Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 2
2003 1
2004 2
2006 3
2007 2
2008 2
2009 3
2010 7
2011 9
2012 9
2013 9
2014 15
2015 10
2016 8
2017 2
2018 4
2019 1
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 27390321

76 results
Results by year
Filters applied: . Clear all
Page 1
Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas.
Daniels D, Guez D, Last D, Hoffmann C, Nass D, Talianski A, Tsarfaty G, Salomon S, Kanner AA, Blumenthal DT, Bokstein F, Harnof S, Yekutieli D, Zamir S, Cohen ZR, Zach L, Mardor Y. Daniels D, et al. AJNR Am J Neuroradiol. 2016 Nov;37(11):2003-2009. doi: 10.3174/ajnr.A4866. Epub 2016 Jul 7. AJNR Am J Neuroradiol. 2016. PMID: 27390321 Free article.
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging.
Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D. Law M, et al. AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98. AJNR Am J Neuroradiol. 2003. PMID: 14625221 Free article.
Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Kickingereder P, et al. Neuro Oncol. 2015 Aug;17(8):1139-47. doi: 10.1093/neuonc/nov028. Epub 2015 Mar 9. Neuro Oncol. 2015. PMID: 25754089 Free PMC article.
Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. Ellingson BM, et al. Radiology. 2014 Apr;271(1):200-10. doi: 10.1148/radiol.13131305. Epub 2013 Nov 27. Radiology. 2014. PMID: 24475840 Free PMC article. Clinical Trial.
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. Harris RJ, et al. Neuro Oncol. 2012 Aug;14(8):1079-89. doi: 10.1093/neuonc/nos141. Epub 2012 Jun 18. Neuro Oncol. 2012. PMID: 22711609 Free PMC article.
Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab.
Bahrami N, Piccioni D, Karunamuni R, Chang YH, White N, Delfanti R, Seibert TM, Hattangadi-Gluth JA, Dale A, Farid N, McDonald CR. Bahrami N, et al. AJNR Am J Neuroradiol. 2018 Jun;39(6):1017-1024. doi: 10.3174/ajnr.A5620. Epub 2018 Apr 5. AJNR Am J Neuroradiol. 2018. PMID: 29622553 Free PMC article.
Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A, Kulle B, Gadmar ØB, Josefsen R, Kumar T, Nakstad PH. Server A, et al. Eur J Radiol. 2011 Nov;80(2):462-70. doi: 10.1016/j.ejrad.2010.07.017. Epub 2010 Aug 13. Eur J Radiol. 2011. PMID: 20708868
Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.
Piludu F, Marzi S, Pace A, Villani V, Fabi A, Carapella CM, Terrenato I, Antenucci A, Vidiri A. Piludu F, et al. Neuroradiology. 2015 Dec;57(12):1269-80. doi: 10.1007/s00234-015-1582-9. Epub 2015 Sep 12. Neuroradiology. 2015. PMID: 26364181 Clinical Trial.
Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
Seeger A, Braun C, Skardelly M, Paulsen F, Schittenhelm J, Ernemann U, Bisdas S. Seeger A, et al. Acad Radiol. 2013 Dec;20(12):1557-65. doi: 10.1016/j.acra.2013.09.003. Acad Radiol. 2013. PMID: 24200483
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab.
Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. Schwarzenberg J, et al. J Nucl Med. 2012 Jan;53(1):29-36. doi: 10.2967/jnumed.111.092387. Epub 2011 Dec 12. J Nucl Med. 2012. PMID: 22159180 Free PMC article. Clinical Trial.
76 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback